Overview of The Drive Episode #399 with Dr. Gayatri Devi
In this episode, Peter Attia speaks with neurologist-psychiatrist Dr. Gayatri Devi about how the understanding and treatment of Alzheimer’s disease and dementia are rapidly evolving. The discussion centers on dementia as a spectrum disorder, the importance of early and personalized diagnosis, the controversial but increasingly refined use of anti-amyloid therapies, and the role of multimodal care that includes vascular risk reduction, hormone management, neurostimulation, and lifestyle interventions. A major theme is that Alzheimer’s is no longer viewed as an inevitably one-way decline; in selected patients, disease stabilization or even improvement may be possible.
Core Takeaways
-
Dementia is not binary
- Alzheimer’s disease, vascular dementia, Lewy body disease, and mixed pathologies often overlap.
- Clinical presentation depends on:
- which brain regions are affected,
- how much cognitive reserve the person has,
- and what comorbid conditions are present.
-
Alzheimer’s is a biologic and clinical syndrome
- Biomarkers matter, but Dr. Devi emphasizes that diagnosis should not rely on biomarkers alone in most cases.
- She favors integrating:
- symptoms,
- function,
- imaging,
- genetics,
- and biomarker data.
-
Early intervention is central
- The earlier pathology is detected, the more potential there is to slow or alter the disease course.
- She believes the field is entering an era where personalized treatment can meaningfully change outcomes.
How Dr. Devi Thinks About Alzheimer’s Disease
Alzheimer’s as a spectrum
- Alzheimer’s is driven by:
- amyloid plaques,
- tau tangles,
- and increasingly recognized neuroinflammation.
- Symptoms may vary widely:
- memory-predominant disease,
- language-predominant disease,
- visuospatial-predominant disease,
- or mixed presentations.
- A single “stage” label can be misleading because different domains may be affected differently.
Pathology may begin decades before symptoms
- The traditional view was that amyloid comes first, followed later by tau and then cognitive decline.
- Dr. Devi argues that inflammatory changes may precede amyloid in some patients.
- This supports a prevention mindset focused on:
- reducing inflammation,
- controlling vascular risk,
- and addressing modifiable exposures early in life.
Diagnostic Approach
Who gets evaluated
- Her practice sees many high-functioning, still-working patients who compensate well.
- Standard screening tools like the MMSE or MoCA may look normal even when meaningful disease is present.
Workup she commonly uses
- Detailed history, including:
- family history,
- vascular risks,
- sleep,
- immune/inflammatory history,
- hormonal history.
- Cognitive testing over several hours.
- Brain electrophysiology.
- Transcranial Doppler / cerebral blood flow assessment.
- MRI with attention to specific regions like:
- hippocampus,
- parietal lobes.
- Amyloid and tau imaging when needed.
- DAT scans when Lewy body or Parkinsonian syndromes are in the differential.
- Blood and/or CSF biomarkers:
- APOE genotype,
- Aβ42/40,
- p-tau markers,
- inflammatory markers.
- Genetic testing for strong early-onset familial syndromes when indicated.
Biomarker caution
- She is skeptical of relying on blood biomarkers alone for diagnosis in asymptomatic or borderline cases.
- Her view:
- amyloid positivity is common with aging,
- so amyloid alone can overcall disease,
- especially without symptoms or tau positivity.
APOE4 and Other Genetics
- APOE4 is a major risk modifier, but not deterministic.
- More deterministic mutations include:
- PSEN1,
- PSEN2,
- APP.
- She describes APOE4/4 as roughly analogous to a strong cancer-risk genotype: not destiny, but very significant risk.
- Family history is important, but many “Alzheimer’s” family histories are actually undiagnosed dementia of unclear subtype because autopsy or biomarker confirmation was often absent.
Inflammation, Infection, and Brain Health
Neuroinflammation as a major frontier
- Dr. Devi believes neuroinflammation may be one of the most important future targets in Alzheimer’s prevention and treatment.
- She highlighted observations suggesting lower Alzheimer’s burden in some people treated aggressively for immune/inflammatory conditions.
Viral and periodontal links
- She discussed possible associations between dementia risk and:
- herpes simplex,
- varicella zoster / shingles,
- gingival/dental inflammation,
- broader inflammatory burden from the gut and immune system.
- The idea is that chronic inflammatory stimuli may contribute to neurodegeneration over time.
Women, Menopause, and Cognition
Menopause-related cognitive impairment
- Dr. Devi coined/uses the idea of menopause-related cognitive impairment.
- Symptoms can mimic early Alzheimer’s:
- word-finding problems,
- executive dysfunction,
- short-term memory issues,
- reduced multitasking ability.
Why women are at higher risk
- Possible contributors:
- loss of estrogen’s brain effects after menopause,
- longer lifespan,
- vascular risk burden,
- immune differences between sexes.
- She notes women often present differently than men:
- more depression/withdrawal,
- more language issues,
- while men may present more with agitation or aggression.
Treatment implications
- When not contraindicated, she supports estrogen therapy in appropriate women.
- She prefers transdermal estrogen when possible because of lower clot/stroke risk.
- She also uses:
- targeted cognitive exercises,
- cholinesterase inhibitors,
- transcranial magnetic stimulation.
Anti-Amyloid Therapies
The drugs discussed
- Aducanumab (first approved, highly controversial)
- Lecanemab
- Donanemab
Why they were controversial
- They clearly reduce amyloid burden, but early concerns centered on:
- limited clinical benefit,
- very high cost,
- and serious risks of:
- ARIA-E (brain edema),
- ARIA-H (microhemorrhage / hemorrhage).
Dr. Devi’s perspective
- She believes the problem may have been:
- treating too late,
- using too aggressive a titration schedule,
- and using the wrong patients.
- She is more optimistic about:
- early use,
- slow titration,
- and careful MRI monitoring.
APOE4/4 patients and ARIA risk
- Patients with two APOE4 alleles are at much higher risk of ARIA.
- Dr. Devi uses very slow titration in such patients and reports lower observed ARIA rates in her practice than historically expected.
- She emphasized that some ARIA is asymptomatic and only detected on MRI.
How ARIA happens
- Antibodies clear amyloid from:
- brain tissue,
- and also the blood vessel walls.
- That can weaken vessel integrity and cause:
- leakage of fluid → edema,
- leakage of blood → hemorrhage.
- Risk is especially concerning in people on anticoagulants.
Cost and access
- The drugs are expensive themselves, and total treatment cost rises with:
- infusion fees,
- MRI monitoring,
- amyloid imaging,
- and insurance barriers.
- Insurance may not cover off-label safer titration strategies.
Multimodal Treatment Strategy
Dr. Devi’s approach is not “drug-only.” She combines multiple interventions based on the patient’s pathology and risk profile.
Common elements of her treatment playbook
- Cholinesterase inhibitors
- e.g. donepezil, galantamine
- Memantine
- Antiviral therapy in selected patients
- e.g. valacyclovir
- Vascular risk reduction
- blood pressure,
- lipids,
- diabetes,
- obesity,
- atrial fibrillation management
- Watchman procedures
- used in some patients so anticoagulation can be stopped, reducing bleeding risk and enabling monoclonal antibody therapy when appropriate
- GLP-1 agonists
- partly for metabolic benefits and possibly direct brain benefits
- Transcranial magnetic stimulation (TMS)
- used off-label, guided by MRI-based neuro-navigation
- targets include dorsolateral prefrontal cortex, Broca’s area, precuneus, and sometimes Wernicke’s area
- Hormone management
- especially in women with menopause-related symptoms
- Brain exercises / cognitive rehabilitation
Vascular Dementia and Lewy Body Disease
Vascular contributions are common
- Pure vascular dementia is less common than mixed disease.
- White matter disease and small strokes are frequent contributors to Alzheimer’s-like decline.
- She is aggressive about treating vascular disease because brain and heart risk are tightly linked.
Lewy body disease is often misdiagnosed
- Many patients with Lewy body disease are misdiagnosed as having Parkinson’s disease.
- That matters because Parkinson’s medications can worsen confusion and psychosis in Lewy body patients.
How she distinguishes Lewy body disease
- Symptoms:
- fluctuating cognition,
- parkinsonism,
- hallucinations,
- often with insight preserved.
- Tools:
- DAT scans,
- alpha-synuclein skin biopsy,
- CSF alpha-synuclein testing in some cases.
- She notes:
- Lewy body and Parkinson’s are part of a broader alpha-synuclein spectrum,
- the distinction is partly defined by timing and clinical pattern.
What Has Changed Her Mind
One of the biggest shifts in Dr. Devi’s thinking:
- She now believes patients with Alzheimer’s can improve, not just decline.
- Before biomarkers and modern therapies, improvement often looked like misdiagnosis.
- Now she believes some improvement is real, especially when:
- disease is detected early,
- treatment is individualized,
- and multiple contributors are addressed.
Future of Dementia Care
What’s next, in her view
- AI-assisted early detection of subtle cognitive change
- Better risk stratification
- Safer and more effective anti-amyloid therapies
- Treatments that directly target neuroinflammation
- More powerful neuromodulation
- Greater personalization based on subtype, genotype, and comorbidity
Her overall message
- Alzheimer’s is highly heterogeneous.
- Treating every patient the same is a mistake.
- The future is:
- early,
- multimodal,
- biomarker-informed,
- and patient-specific.
Practical Recommendations Implied by the Episode
- Don’t dismiss subtle cognitive complaints in high-functioning patients.
- Consider mixed pathology rather than a single diagnosis.
- Confirm “Alzheimer’s” with more than one data source when possible.
- Be cautious with asymptomatic screening unless risk is high.
- In women, always consider menopause/hormone status as part of cognitive assessment.
- In suspected Lewy body disease, be careful with dopamine-enhancing therapy.
- For high-risk patients on anti-amyloid therapy, use:
- slow titration,
- close MRI monitoring,
- and anticoagulation review.